WHO ICTRP trial
Favipiravir for SARS-CoV-infected patients
JPRN-jRCTs041190120 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs041190120 |
|---|---|
| Public title | Favipiravir for SARS-CoV-infected patients |
| Scientific title | Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction |
| Primary sponsor | Doi Yohei |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | COVID-19 infection COVID-19 infection;COVID-19 infection |
| Interventions | Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2 Delayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15… |
| Registration date | Feb 3, 2020 |
| Target size | 86 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: